[HTML][HTML] Early outpatient treatment for Covid-19 with convalescent plasma
…, DM Shade, S Ehrhardt, SN Baksh… - … England Journal of …, 2022 - Mass Medical Soc
Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing …
The effects of four doses of vitamin D supplements on falls in older adults: a response-adaptive, randomized clinical trial
…, J Charleston, M Minotti, SN Baksh… - Annals of internal …, 2021 - acpjournals.org
Background: Vitamin D supplementation may prevent falls in older persons, but evidence is
inconsistent, possibly because of dosage differences. Objective: To compare the effects of 4 …
inconsistent, possibly because of dosage differences. Objective: To compare the effects of 4 …
[HTML][HTML] Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma
…, DA Jabs, LJ Appel, DM Shade, S Ehrhardt, SN Baksh… - Medrxiv, 2021 - ncbi.nlm.nih.gov
BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent
serious complications of COVID-19 in outpatients with recent onset of illness is uncertain. …
serious complications of COVID-19 in outpatients with recent onset of illness is uncertain. …
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial
Introduction Alzheimer's disease (AD) is a disabling, common cause of dementia, and agitation
is one of the most common and distressing symptoms for patients with AD. Escitalopram …
is one of the most common and distressing symptoms for patients with AD. Escitalopram …
Transfusion reactions associated with COVID‐19 convalescent plasma in outpatient clinical trials
Background COVID‐19 convalescent plasma (CCP) is an important therapeutic option for
outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety …
outpatients at high risk of hospitalization from SARS‐CoV‐2 infection. We assessed the safety …
[HTML][HTML] Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis
…, DO Scharfstein, T Li, P Khanal, SN Baksh, N McBee… - PloS one, 2022 - journals.plos.org
Background Results from observational studies and randomized clinical trials (RCTs) have
led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective …
led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective …
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
SN Baksh, SL Heath, Y Fukuta, D Shade… - The Journal of …, 2023 - academic.oup.com
Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces
hospitalizations among outpatients treated early after symptom onset. It is unknown whether …
hospitalizations among outpatients treated early after symptom onset. It is unknown whether …
Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations.
…, DM Shade, B Lau, S Ehrhardt, SN Baksh… - Medrxiv: the Preprint …, 2023 - europepmc.org
SARS-CoV-2 antibody levels associated with reduced hospitalization risk remain undefined.
Our outpatient COVID-19 convalescent plasma (CCP), placebo-controlled trial observed …
Our outpatient COVID-19 convalescent plasma (CCP), placebo-controlled trial observed …
[HTML][HTML] Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
SN Baksh, JB Segal, M McAdams-DeMarco… - PloS one, 2020 - journals.plos.org
Background Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients
without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 …
without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 …
Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients
SN Baksh, M McAdams‐DeMarco… - … and drug safety, 2018 - Wiley Online Library
Purpose In 2008, the US Food and Drug Administration (FDA) issued Draft Guidance on
investigating cardiovascular risk with oral diabetic drugs, including dipeptidyl peptidase‐4 …
investigating cardiovascular risk with oral diabetic drugs, including dipeptidyl peptidase‐4 …